Articles tagged with Combination Therapies
Researchers found that combining 308-nm excimer laser therapy with topical tacrolimus ointment resulted in 100% repigmentation in group A lesions and 85% in group B. The treatment was well tolerated, with an average of 10-12 sessions needed to see improvement.
A Phase III trial found that CAMPTOSAR combinations with select targeted agents improve survival for MCRC patients. The combination of Avastin and IFL yields an average survival of 25.1 months compared to 15.8 months with IFL alone. A Phase II trial also shows the efficacy of Erbitux plus CAMPTOSAR and infusional FOLFIRI in EGFR-expres...
The CAMPTOSAR plus cisplatin regimen demonstrated improved one-year survival rates (59.2%) and response rates (31%) compared to current standard treatments. Patient toxicities were also significantly reduced, with fewer grade 3-4 neutropenia and thrombocytopenia cases.
A study by Chandra P. Belani and colleagues found that elderly patients with advanced NSCLC can tolerate combination therapy safely and effectively, with median survival rates comparable to those of younger patients. The treatment regimens used in the study were weekly paclitaxel in combination with full doses of carboplatin.
Researchers found that patients with combined devices showed significant improvements in quality of life, physical functioning, and exercise capacity compared to those without the devices. The study's findings have implications for treating heart failure, a disease with a five-year mortality rate of 50 percent after diagnosis.
A new study published in JAMA found that a combination therapy of hormone replacement and alendronate was well-tolerated by elderly women with low bone mass. After three years, participants taking the combination therapy showed significantly greater increases in bone mass compared to those taking individual therapies.
Researchers found that aspirin use did not decrease the effectiveness of ACE inhibitor therapy in patients. The combination of both treatments significantly reduced major vascular outcomes by 22%, producing substantial additional benefits for patients at high risk of events.
A nationwide survey of over 800 adults found that patients who use both traditional and CAM therapies view their healthcare providers as part of a larger team. More than half of respondents believed CAM therapies were more helpful for certain conditions, but had equal trust in physicians as practitioners.
A large clinical trial found that hormone replacement therapy with estrogen and progestin did not increase or decrease the risk of stroke among postmenopausal women with heart disease. The study's lead author cautioned that the results may not apply to all women taking hormone therapy, and more research is needed.
A clinical trial of Mylotarg found disease remission in 34% of patients under 60 and 26% of those over 60, with a median overall survival of 5.9 months. No significant differences were seen in adverse events between age groups.
Researchers found that combining radiation therapy with androgen suppression therapy significantly reduced the risk of PSA failure in men with intermediate- and high-risk prostate cancer. The treatment showed efficacy even in low-risk patients, suggesting a potential benefit for all early-stage prostate cancer patients.
A study of postmenopausal women in Los Angeles County found that long-term use of hormone replacement therapy combining estrogen and progestin increases breast cancer risk by 24%. The risk was highest for sequential therapy, but continuous combined therapy showed lower risks. Researchers suggest lowering doses to decrease disease risk.
A study suggests that triple-drug treatment regimens are superior to less intensive therapies in maintaining HIV suppression. Researchers found that patients who switched from three-drug to two- or one-drug treatment regimens were more likely to experience a resurgence in their HIV levels.
A large-scale study shows that estrogen replacement therapy, with or without progestin, consistently and sustainably reduces plasma lipoprotein (a) concentrations, a high-risk factor for heart attacks and strokes. The results also confirm hormone therapy's broad-scale impact on cholesterol metabolism.
Researchers studied 1,947 women and found that taking progestin with estrogen therapy reduces risk of endometrial cancer by four-fold, but risks increase with shorter progestin cycles. Women who took combination therapy for over five years had a higher risk of endometrial cancer compared to non-users.